Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma

Observational Study of the Clinical Practice in Patients With Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma in Greece

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03266757

Enrollment

200

Registered

2017-08-30

Start date

2016-02-11

Completion date

2018-02-11

Last updated

2019-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Adenocarcinoma

Brief summary

Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients Age 18 or older with histologically confirmed ductal pancreatic adenocarcinoma as a primary tumor * Patients with ductal pancreatic adenocarcinoma (Borderline resectable or resectable or advanced) * Patients that are alive and under treatment or follow up * Signed informed consent (ICF)

Exclusion criteria

* Presence of other primary tumors * Pancreatic adenocarcinoma due to metastasis from other primary tumor(s) * Neuroendocrine or other pancreatic carcinoma other than ductal adenocarcinoma * Patients who refuse to provide informed consent

Design outcomes

Primary

Measure	Time frame
clinical practice-treatments	2 years

Secondary

Measure	Time frame
progression Free Survival	2 years
Overall Survival	2 years

Outcome results